MedTrace Logo

Post-Acute COVID-19, Inflammation, and Depression

NCT05346120 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-12-13

No results posted yet for this study

Summary

Single site, double blind, placebo-controlled, longitudinal study of depression in Subjects with COVID- 19 long haulers syndrome using a 1:1 ratio randomization for a single IV infusion of 6 million cells/kg allogeneic marrow stromal cells (MSCs).

Conditions

  • Post COVID -19 Depression

Interventions

BIOLOGICAL

allogeneic marrow stromal cells (MSCs)

stem cell infusion

Sponsors & Collaborators

  • Sean Savitz

    lead OTHER

Principal Investigators

  • Susan E Alderman, PhD · UTHealth Science Center Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-25
Primary Completion
2023-12-20
Completion
2024-05-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05346120 on ClinicalTrials.gov